Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…
Three years after being merged with QLT the Aegerion business is to be sold out of bankruptcy protection.
The group is desperately playing up mirvetuximab, but its future rests with a pair of earlier-stage projects.
Expectations are low for a three-year update on the group’s haemophilia A gene therapy, and Biomarin’s rivals could capitalise on any slip-up.
Hopes are high as a phase III readout approaches for Reata Pharmaceuticals’ lead project, bardoxolone.
The small-molecule oncology player zeroes in on its first commercial opportunity.
While praising Novartis for kickstarting the CAR-T revolution, the chief exec of Tmunity has no doubt where cell therapy’s development engine really lies.
Its gene therapy is three years away from market, but Mustang is already thinking about outcomes-based pricing.
Astrazeneca has made another push into artificial intelligence, but admits that it will be some time before it knows whether the technology has helped its drug discovery…